Clinical trials: Colonic Diseases
Colorectal Cancer
Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy
Participants with metastatic Colorectal Cancer (mCRC) who have progressed on a prior Anti-epidermal growth factor receptor (EGFR) regimen randomized to receive IMC-A12 monotherapy or combination therapy with cetuximab to assess…
- Trial name
- NCT00503685
- Testing
- IMC-A12, cetuximab
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- Eli Lilly and Company
Crohn's Disease
PillCam® Platform With the PillCam Crohn's Disease Capsule
This is a prospective, multi-center (up to 6 sites) study which aims to To establish the effectiveness of the PillCam Platform with the PillCam Crohn's capsule as demonstrated by visualizing the small bowel and colon in patients…
- Trial name
- NCT01631435
- Testing
- Pillcam colon capsule and PillCam™ Prep Procedure, Ileocolonoscopy
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Medtronic - MITG
Lynch Syndrome
Colonoscopy Check-up in People With Lynch Syndrome
Lynch syndrome, an inherited condition, increases bowel cancer risk. People with Lynch syndrome are recommended to have regular colonoscopies where a camera in a tube is used to look inside the bowel for cancer and for polyps…
- Trial name
- NCT06126120
- Where
- United Kingdom
- Volunteers
- 231 people
- Sponsor
- Imperial College London
Colorectal Cancer Screening
Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation
The rate of screening for colorectal cancer (CRC) in the U.S. remains low (under 65%), meaning that thousands of people die of colorectal cancer unnecessarily.
- Trial name
- NCT04683744
- Testing
- Semi-structured interviews-Patients, Semi-structured interviews-Health system
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Indiana University
Stage IV Colon Cancer, Stage IV Rectal Cancer
High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer
This phase II trial is studying how well giving high-dose cholecalciferol works in treating patients receiving combination chemotherapy and bevacizumab as first-line therapy for metastatic colorectal cancer.
- Trial name
- NCT01198548
- Testing
- leucovorin calcium, bevacizumab, cholecalciferol
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Roswell Park Cancer Institute
Colorectal Cancer
Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00390364
- Testing
- everolimus, antiangiogenesis therapy, biopsy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Cancer Screening
Information With or Without Numbers For Optimizing Reasoning About Medical Decisions
Experts believe that increasing the low uptake of screening for colorectal cancer (CRC) requires educating patients about all approved tests and helping them choose one that fits their preferences.
- Trial name
- INFORM (NCT02477553)
- Testing
- DA - Quantitative, DA - Verbal
- Where
- United States
- Volunteers
- 728 people
- Sponsor
- Indiana University
Ulcerative Colitis
MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients
This is a multi-centre, randomised, double-blind, placebo controlled, parallel group, Phase II study to evaluate efficacy and safety of 3 doses of MEDI7183, in Japanese subjects with moderate to severe UC
- Trial name
- NCT01959165
- Testing
- MEDI7183 low dose, MEDI7183 medium dose, MEDI7183 high dose
- Where
- 23 sites in Japan
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Liver Neoplasms
Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
This study is an open label prospective trial of TheraSphere treatment for patients who have liver metastases who have failed or are intolerant to other systemic or liver directed therapies.
- Trial name
- NCT01177007
- Testing
- TheraSphere, Yttrium-90 glass Microspheres
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Metastatic Colorectal Cancer
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
The primary objective of this study is to compare the effect of panitumumab versus cetuximab on overall survival (OS) for chemorefractory metastatic colorectal cancer (mCRC) among patients with wild-type Kirsten rat Sarcoma-2…
- Trial name
- NCT01001377
- Testing
- Cetuximab, Panitumumab
- Where
- 152 sites in United States, Australia and 27 more
- Volunteers
- 1,010 people
- Sponsor
- Amgen
Anemia, Breast Cancer
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
This is a multicenter, international, prospective, observational study of patients who are receiving systemic chemotherapy for solid tumour cancers (breast, colorectal, ovarian, prostate, lung, bladder, endometrial, renal…
- Conditions
- Anemia, Breast Cancer, Cancer, Colorectal Cancer
- Trial name
- NCT01444456
- Where
- 117 sites in Austria, Belgium and 7 more
- Volunteers
- 1,262 people
- Sponsor
- Amgen
Colorectal Cancer
Radial Reload Laparoscopic LAR Case Series
To evaluate the Radial Reload Stapler during laparoscopic low anterior resection (LAR) or anterior proctosigmoidectomy for rectal cancer by assessing the primary and secondary endpoints.
- Trial name
- NCT01706822
- Testing
- Covidien Radial Reload Stapler with Tri-Staple Technology
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Medtronic - MITG
Metastatic Solid Tumor, Colorectal Cancer
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors.
- Conditions
- Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer
- Trial name
- NCT04579757
- Testing
- Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2
- Where
- 18 sites in United States
- Volunteers
- 87 people
- Sponsor
- Hutchmed
Adenomatous Polyposis Coli
Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)
To test whether celecoxib can be used to prevent colon polyp formation in children with familial adenomatous polyposis (FAP).
- Trial name
- CHIP (NCT00585312)
- Testing
- Celecoxib
- Where
- 42 sites in United States, Belgium and 12 more
- Volunteers
- 106 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Rectal Cancer
Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer
This trial will enroll patients with locally advanced rectal cancer (resectable and non-resectable).The phase Ib dose escalation portion of trial is designed to determine the maximum tolerated dose (MTD) of CRLX101 when combined…
- Trial name
- NCT02010567
- Testing
- CRLX101, Capecitabine, Radiotherapy
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colorectal Cancer
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
The objective of this study is to compare the progression free survival (PFS), overall survival (OS), objective response rate (ORR), time to treatment failure (TTF), duration of response (DoR), quality of life, safety and…
- Trial name
- NCT01478594
- Testing
- Tivozanib, Bevacizumab, mFOLFOX6
- Where
- 73 sites in United States, Australia and 10 more
- Volunteers
- 265 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Colorectal Cancer
Magnesium Treatment on Vitamin D Metabolism in Participants Completed Personalized Prevention of Colorectal Cancer Trial
One striking observation is that a large portion of the inter-person variation in serum 25-hydroxyvitamin D (25(OH)D) levels is unexplained.
- Trial name
- NCT03265483
- Testing
- Magnesium glycinate
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Colorectal Neoplasms
Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer
The objective of this trial is to evaluate the safety and tolerability of BI 695502 in combination with leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) and as maintenance therapy (when applicable).
- Trial name
- INVICTAN®-3 (NCT02776683)
- Testing
- BI 695502, Avastin
- Where
- 46 sites in United States, Japan and 2 more
- Volunteers
- 123 people
- Sponsor
- Boehringer Ingelheim
Functional Bowel Disorders
Open Label Seroquel (Quetiapine) Study for Treatment Resistant Functional Bowel Disorder
Purpose: We are proposing to examine, via open label trial, the use of Seroquel® for patients with moderate to severe functional bowel symptoms who are not receiving adequate relief from their symptoms on their present regimen of…
- Trial name
- NCT00617396
- Testing
- Quetiapine (50 mg/day-100mg/day)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of North Carolina, Chapel Hill
Metastatic Colorectal Cancer
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
This is a randomized, double-blind, placebo-controlled multi-center phase III study to evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed on/after all approved…
- Trial name
- NCT01103323
- Testing
- Regorafenib (Stivarga, BAY73-4506), Best Supportive Care (BSC)
- Where
- 171 sites in United States, Argentina and 17 more
- Volunteers
- 760 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.